331 related articles for article (PubMed ID: 25871400)
21. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
Xu T; Zhang J; Chen W; Pan S; Zhi X; Wen L; Zhou Y; Chen BW; Qiu J; Zhang Y; Yang Q; Feng X; Bai X; Liang T
Cancer Lett; 2016 Jul; 377(2):140-8. PubMed ID: 27126361
[TBL] [Abstract][Full Text] [Related]
22. Increase of miR-199a-5p by protoporphyrin IX, a photocatalyzer, directly inhibits E2F3, sensitizing mesenchymal tumor cells to anti-cancer agents.
Lee JM; Heo MJ; Lee CG; Yang YM; Kim SG
Oncotarget; 2015 Feb; 6(6):3918-31. PubMed ID: 25714015
[TBL] [Abstract][Full Text] [Related]
23. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
24. BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma.
Ma J; Zeng S; Zhang Y; Deng G; Qu Y; Guo C; Yin L; Han Y; Cai C; Li Y; Wang G; Bonkovsky HL; Shen H
Cancer Lett; 2017 Dec; 411():117-129. PubMed ID: 28987388
[TBL] [Abstract][Full Text] [Related]
25. Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis.
Liu L; Zhu XD; Wang WQ; Shen Y; Qin Y; Ren ZG; Sun HC; Tang ZY
Clin Cancer Res; 2010 May; 16(10):2740-50. PubMed ID: 20460486
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma.
Liang C; Dong Z; Cai X; Shen J; Xu Y; Zhang M; Li H; Yu W; Chen W
Cell Death Dis; 2020 Nov; 11(11):1017. PubMed ID: 33250518
[TBL] [Abstract][Full Text] [Related]
27. Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization.
Fei M; Lu M; Wang Y; Zhao Y; He S; Gao S; Ke Q; Liu Y; Li P; Cui X; Shen A; Cheng C
Med Oncol; 2009; 26(2):178-85. PubMed ID: 18937079
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion.
Chen L; Yuan YF; Li Y; Chan TH; Zheng BJ; Huang J; Guan XY
Gut; 2011 Apr; 60(4):534-43. PubMed ID: 21068133
[TBL] [Abstract][Full Text] [Related]
29. Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.
Tan J; Ye J; Song M; Zhou M; Hu Y
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29112301
[TBL] [Abstract][Full Text] [Related]
30. Codelivery of salinomycin and doxorubicin using nanoliposomes for targeting both liver cancer cells and cancer stem cells.
Gong Z; Chen D; Xie F; Liu J; Zhang H; Zou H; Yu Y; Chen Y; Sun Z; Wang X; Zhang H; Zhang G; Yin C; Gao J; Zhong Y; Lu Y
Nanomedicine (Lond); 2016 Oct; 11(19):2565-2579. PubMed ID: 27647449
[TBL] [Abstract][Full Text] [Related]
31. The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles.
Jiang J; Chen H; Yu C; Zhang Y; Chen M; Tian S; Sun C
Nanomedicine (Lond); 2015 Jul; 10(12):1863-79. PubMed ID: 26139123
[TBL] [Abstract][Full Text] [Related]
32. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
33. Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance.
Zhang Y; Zeng S; Ma J; Deng G; Qu Y; Guo C; Shen H
J Exp Clin Cancer Res; 2016 Jul; 35(1):111. PubMed ID: 27412382
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma.
Xia L; Huang W; Tian D; Zhu H; Qi X; Chen Z; Zhang Y; Hu H; Fan D; Nie Y; Wu K
Hepatology; 2013 Feb; 57(2):610-24. PubMed ID: 22911555
[TBL] [Abstract][Full Text] [Related]
35. Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer.
Renard CA; Labalette C; Armengol C; Cougot D; Wei Y; Cairo S; Pineau P; Neuveut C; de Reyniès A; Dejean A; Perret C; Buendia MA
Cancer Res; 2007 Feb; 67(3):901-10. PubMed ID: 17283120
[TBL] [Abstract][Full Text] [Related]
36. 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.
Hu XY; Liang JY; Guo XJ; Liu L; Guo YB
Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):146-53. PubMed ID: 25363523
[TBL] [Abstract][Full Text] [Related]
37. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
38. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
Fang L; Wang H; Zhou L; Yu D
Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
[TBL] [Abstract][Full Text] [Related]
39. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells.
Hu QD; Chen W; Yan TL; Ma T; Chen CL; Liang C; Zhang Q; Xia XF; Liu H; Zhi X; Zheng XX; Bai XL; Yu XZ; Liang TB
Cancer Lett; 2012 Dec; 325(2):207-13. PubMed ID: 22781398
[TBL] [Abstract][Full Text] [Related]
40. Differentiation therapy of hepatocellular carcinoma by inhibiting the activity of AKT/GSK-3β/β-catenin axis and TGF-β induced EMT with sophocarpine.
Zhang PP; Wang PQ; Qiao CP; Zhang Q; Zhang JP; Chen F; Zhang X; Xie WF; Yuan ZL; Li ZS; Chen YX
Cancer Lett; 2016 Jun; 376(1):95-103. PubMed ID: 26945965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
